336 related articles for article (PubMed ID: 20428949)
1. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.
Sloots CE; Rykx A; Cools M; Kerstens R; De Pauw M
Dig Dis Sci; 2010 Oct; 55(10):2912-21. PubMed ID: 20428949
[TBL] [Abstract][Full Text] [Related]
2. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
Tack J; van Outryve M; Beyens G; Kerstens R; Vandeplassche L
Gut; 2009 Mar; 58(3):357-65. PubMed ID: 18987031
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled trial of prucalopride for severe chronic constipation.
Camilleri M; Kerstens R; Rykx A; Vandeplassche L
N Engl J Med; 2008 May; 358(22):2344-54. PubMed ID: 18509121
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
Quigley EM; Vandeplassche L; Kerstens R; Ausma J
Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation.
Yiannakou Y; Piessevaux H; Bouchoucha M; Schiefke I; Filip R; Gabalec L; Dina I; Stephenson D; Kerstens R; Etherson K; Levine A
Am J Gastroenterol; 2015 May; 110(5):741-8. PubMed ID: 25869393
[TBL] [Abstract][Full Text] [Related]
6. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride.
Tack J; Camilleri M; Dubois D; Vandeplassche L; Joseph A; Kerstens R
Neurogastroenterol Motil; 2015 Mar; 27(3):397-405. PubMed ID: 25581251
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury.
Krogh K; Jensen MB; Gandrup P; Laurberg S; Nilsson J; Kerstens R; De Pauw M
Scand J Gastroenterol; 2002 Apr; 37(4):431-6. PubMed ID: 11989834
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety analysis of prucalopride in refractory chronic constipation cases in a tertiary care hospital in Eastern India: A randomized, single-blind, placebo-controlled study.
Dehury S; Mohapatra S; Das HS; Goutam S; Kaushik C
Indian J Pharmacol; 2023; 55(1):6-13. PubMed ID: 36960515
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment.
Cinca R; Chera D; Gruss HJ; Halphen M
Aliment Pharmacol Ther; 2013 May; 37(9):876-86. PubMed ID: 23480216
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.
Cryer B; Katz S; Vallejo R; Popescu A; Ueno R
Pain Med; 2014 Nov; 15(11):1825-34. PubMed ID: 24716835
[TBL] [Abstract][Full Text] [Related]
11. Effect of prucalopride on symptoms of chronic constipation.
Tack J; Stanghellini V; Dubois D; Joseph A; Vandeplassche L; Kerstens R
Neurogastroenterol Motil; 2014 Jan; 26(1):21-7. PubMed ID: 24106924
[TBL] [Abstract][Full Text] [Related]
12. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial.
Coremans G; Kerstens R; De Pauw M; Stevens M
Digestion; 2003; 67(1-2):82-9. PubMed ID: 12743445
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis.
Tack J; Quigley E; Camilleri M; Vandeplassche L; Kerstens R
United European Gastroenterol J; 2013 Feb; 1(1):48-59. PubMed ID: 24917940
[TBL] [Abstract][Full Text] [Related]
14. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study.
Camilleri M; Beyens G; Kerstens R; Robinson P; Vandeplassche L
Neurogastroenterol Motil; 2009 Dec; 21(12):1256-e117. PubMed ID: 19751247
[TBL] [Abstract][Full Text] [Related]
15. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study.
Ke M; Zou D; Yuan Y; Li Y; Lin L; Hao J; Hou X; Kim HJ
Neurogastroenterol Motil; 2012 Nov; 24(11):999-e541. PubMed ID: 22882724
[TBL] [Abstract][Full Text] [Related]
16. Prucalopride.
Frampton JE
Drugs; 2009; 69(17):2463-76. PubMed ID: 19911858
[TBL] [Abstract][Full Text] [Related]
17. Prucalopride: a review of its use in the management of chronic constipation.
Keating GM
Drugs; 2013 Nov; 73(17):1935-50. PubMed ID: 24194435
[TBL] [Abstract][Full Text] [Related]
18. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation.
Sloots CE; Poen AC; Kerstens R; Stevens M; De Pauw M; Van Oene JC; Meuwissen SG; Felt-Bersma RJ
Aliment Pharmacol Ther; 2002 Apr; 16(4):759-67. PubMed ID: 11929394
[TBL] [Abstract][Full Text] [Related]
19. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Webster LR; Yamada T; Arjona Ferreira JC
Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
[TBL] [Abstract][Full Text] [Related]
20. Prucalopride is no more effective than placebo for children with functional constipation.
Mugie SM; Korczowski B; Bodi P; Green A; Kerstens R; Ausma J; Ruth M; Levine A; Benninga MA
Gastroenterology; 2014 Dec; 147(6):1285-95.e1. PubMed ID: 25239590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
